283 related articles for article (PubMed ID: 23658612)
1. Effective exon skipping and dystrophin restoration by 2'-o-methoxyethyl antisense oligonucleotide in dystrophin-deficient mice.
Yang L; Niu H; Gao X; Wang Q; Han G; Cao L; Cai C; Weiler J; Yin H
PLoS One; 2013; 8(4):e61584. PubMed ID: 23658612
[TBL] [Abstract][Full Text] [Related]
2. Effective exon skipping and restoration of dystrophin expression by peptide nucleic acid antisense oligonucleotides in mdx mice.
Yin H; Lu Q; Wood M
Mol Ther; 2008 Jan; 16(1):38-45. PubMed ID: 17968354
[TBL] [Abstract][Full Text] [Related]
3. In vitro evaluation of novel antisense oligonucleotides is predictive of in vivo exon skipping activity for Duchenne muscular dystrophy.
Wang Q; Yin H; Camelliti P; Betts C; Moulton H; Lee H; Saleh AF; Gait MJ; Wood MJ
J Gene Med; 2010 Apr; 12(4):354-64. PubMed ID: 20235089
[TBL] [Abstract][Full Text] [Related]
4. Systematic evaluation of 2'-Fluoro modified chimeric antisense oligonucleotide-mediated exon skipping in vitro.
Chen S; Le BT; Chakravarthy M; Kosbar TR; Veedu RN
Sci Rep; 2019 Apr; 9(1):6078. PubMed ID: 30988454
[TBL] [Abstract][Full Text] [Related]
5. Quantitative Antisense Screening and Optimization for Exon 51 Skipping in Duchenne Muscular Dystrophy.
Echigoya Y; Lim KRQ; Trieu N; Bao B; Miskew Nichols B; Vila MC; Novak JS; Hara Y; Lee J; Touznik A; Mamchaoui K; Aoki Y; Takeda S; Nagaraju K; Mouly V; Maruyama R; Duddy W; Yokota T
Mol Ther; 2017 Nov; 25(11):2561-2572. PubMed ID: 28865998
[TBL] [Abstract][Full Text] [Related]
6. Wild-type mouse models to screen antisense oligonucleotides for exon-skipping efficacy in Duchenne muscular dystrophy.
Cao L; Han G; Gu B; Yin H
PLoS One; 2014; 9(11):e111079. PubMed ID: 25365558
[TBL] [Abstract][Full Text] [Related]
7. Induction of dystrophin expression by exon skipping in mdx mice following intramuscular injection of antisense oligonucleotides complexed with PEG-PEI copolymers.
Williams JH; Sirsi SR; Latta DR; Lutz GJ
Mol Ther; 2006 Jul; 14(1):88-96. PubMed ID: 16488666
[TBL] [Abstract][Full Text] [Related]
8. Dantrolene enhances antisense-mediated exon skipping in human and mouse models of Duchenne muscular dystrophy.
Kendall GC; Mokhonova EI; Moran M; Sejbuk NE; Wang DW; Silva O; Wang RT; Martinez L; Lu QL; Damoiseaux R; Spencer MJ; Nelson SF; Miceli MC
Sci Transl Med; 2012 Dec; 4(164):164ra160. PubMed ID: 23241744
[TBL] [Abstract][Full Text] [Related]
9. Nonclinical Exon Skipping Studies with 2'-O-Methyl Phosphorothioate Antisense Oligonucleotides in mdx and mdx-utrn-/- Mice Inspired by Clinical Trial Results.
van Putten M; Tanganyika-de Winter C; Bosgra S; Aartsma-Rus A
Nucleic Acid Ther; 2019 Apr; 29(2):92-103. PubMed ID: 30672725
[TBL] [Abstract][Full Text] [Related]
10. Targeted skipping of human dystrophin exons in transgenic mouse model systemically for antisense drug development.
Wu B; Benrashid E; Lu P; Cloer C; Zillmer A; Shaban M; Lu QL
PLoS One; 2011; 6(5):e19906. PubMed ID: 21611204
[TBL] [Abstract][Full Text] [Related]
11. Dual exon skipping in myostatin and dystrophin for Duchenne muscular dystrophy.
Kemaladewi DU; Hoogaars WM; van Heiningen SH; Terlouw S; de Gorter DJ; den Dunnen JT; van Ommen GJ; Aartsma-Rus A; ten Dijke P; 't Hoen PA
BMC Med Genomics; 2011 Apr; 4():36. PubMed ID: 21507246
[TBL] [Abstract][Full Text] [Related]
12. Next Generation Exon 51 Skipping Antisense Oligonucleotides for Duchenne Muscular Dystrophy.
van Deutekom J; Beekman C; Bijl S; Bosgra S; van den Eijnde R; Franken D; Groenendaal B; Harquouli B; Janson A; Koevoets P; Mulder M; Muilwijk D; Peterburgska G; Querido B; Testerink J; Verheul R; de Visser P; Weij R; Aartsma-Rus A; Puoliväli J; Bragge T; O'Neill C; Datson NA
Nucleic Acid Ther; 2023 Jun; 33(3):193-208. PubMed ID: 37036788
[TBL] [Abstract][Full Text] [Related]
13. Antisense oligonucleotide induced exon skipping and the dystrophin gene transcript: cocktails and chemistries.
Adams AM; Harding PL; Iversen PL; Coleman C; Fletcher S; Wilton SD
BMC Mol Biol; 2007 Jul; 8():57. PubMed ID: 17601349
[TBL] [Abstract][Full Text] [Related]
14. In Vitro Multiexon Skipping by Antisense PMOs in Dystrophic Dog and Exon 7-Deleted DMD Patient.
Nakamura A; Aoki Y; Tsoumpra M; Yokota T; Takeda S
Methods Mol Biol; 2018; 1828():151-163. PubMed ID: 30171540
[TBL] [Abstract][Full Text] [Related]
15. Antisense oligonucleotide-induced exon skipping restores dystrophin expression in vitro in a canine model of DMD.
McClorey G; Moulton HM; Iversen PL; Fletcher S; Wilton SD
Gene Ther; 2006 Oct; 13(19):1373-81. PubMed ID: 16724091
[TBL] [Abstract][Full Text] [Related]
16. Skipping multiple exons of dystrophin transcripts using cocktail antisense oligonucleotides.
Echigoya Y; Yokota T
Nucleic Acid Ther; 2014 Feb; 24(1):57-68. PubMed ID: 24380394
[TBL] [Abstract][Full Text] [Related]
17. Bodywide skipping of exons 45-55 in dystrophic mdx52 mice by systemic antisense delivery.
Aoki Y; Yokota T; Nagata T; Nakamura A; Tanihata J; Saito T; Duguez SM; Nagaraju K; Hoffman EP; Partridge T; Takeda S
Proc Natl Acad Sci U S A; 2012 Aug; 109(34):13763-8. PubMed ID: 22869723
[TBL] [Abstract][Full Text] [Related]
18. Optimizing RNA/ENA chimeric antisense oligonucleotides using in vitro splicing.
Takeshima Y; Yagi M; Matsuo M
Methods Mol Biol; 2012; 867():131-41. PubMed ID: 22454059
[TBL] [Abstract][Full Text] [Related]
19. Antisense oligo-mediated multiple exon skipping in a dog model of duchenne muscular dystrophy.
Yokota T; Hoffman E; Takeda S
Methods Mol Biol; 2011; 709():299-312. PubMed ID: 21194037
[TBL] [Abstract][Full Text] [Related]
20. A fusion peptide directs enhanced systemic dystrophin exon skipping and functional restoration in dystrophin-deficient mdx mice.
Yin H; Moulton HM; Betts C; Seow Y; Boutilier J; Iverson PL; Wood MJ
Hum Mol Genet; 2009 Nov; 18(22):4405-14. PubMed ID: 19692354
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
